Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 2,678 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,678 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $38.09, for a total value of $102,005.02. Following the completion of the sale, the insider owned 30,852 shares in the company, valued at $1,175,152.68. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Price Performance

NASDAQ CSTL traded up $0.54 during trading on Wednesday, hitting $40.61. 274,232 shares of the stock traded hands, compared to its average volume of 398,331. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $42.17. The firm has a 50-day simple moving average of $36.73 and a 200-day simple moving average of $26.50. The company has a market capitalization of $1.19 billion, a P/E ratio of -90.24 and a beta of 1.06.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The firm had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. As a group, analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in CSTL. Farther Finance Advisors LLC increased its holdings in Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Castle Biosciences in the 3rd quarter worth $35,000. CWM LLC grew its stake in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after buying an additional 853 shares during the last quarter. Russell Investments Group Ltd. increased its position in Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after buying an additional 976 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on CSTL shares. Guggenheim lifted their price target on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. BTIG Research boosted their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Finally, Robert W. Baird raised their price target on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $43.17.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.